Difference between revisions of "Part:BBa K2235010"
(→Important Parameters) |
(→Important Parameters) |
||
Line 16: | Line 16: | ||
===Important Parameters=== | ===Important Parameters=== | ||
− | [[File:EBGComp_Parameter.png|600px|thumb|left| | + | [[File:EBGComp_Parameter.png|600px|thumb|left|Table 1: Parameters used for expression and purification of EBG enzyme.]] |
<p align="justify"> | <p align="justify"> |
Revision as of 10:05, 28 October 2017
Endo beta galactosidase with T7 promoter, RBS and functional unit
Introduction
BBa_K2235010 biobrick is a composite of a T7 promoter and RBS followed by endo-β-galactosidase enzyme coding site which is N-terminally attached to a His-tag. This enzyme has been shown to release saccharide chains from glycans expressed in gastric mucus. It performs this action by hydrolysing the bonds next to galactose saccharides in the polysaccharide chains of mucins. The sequence originates from the species Clostridium Perfringens. The basic part BBa_K2235008 consists of the endo beta galactosidase enzyme coding sequence with a His-tag N-terminally attached.
Usage and Biology
The endo-β-galactosidase (Endo-β-GalGnGa) was originally expressed from Clostridium perfringens. This bacteria strain is capable of releasing GlcNAcα1→4Gal from glycans expressed in the gastric mucous cell-type mucin [1]. This enzyme specifically releases the disaccharide GlcNAcR1f 4Gal from O-glycans expressed in the gastric gland mucous cell-type mucin. This enzyme has been shown to hydrolyze the endo-â-galactosyl linkage not only in the GlcNAcR1f 4Galâ1f4GlcNAc sequence but also in GlcNAcR1f 4Galâ1f3GalNAcR1fSer/Thr. Endo-â-GalGnGa is distinct from the hitherto known endo-â-galactosidases because of its strict specificity for releasing the disaccharide GlcNAcR1f 4Gal. To characterize Endo-â-GalGnGa, we have carried out the molecular cloning of this endoglycosidase. Here we describe the cloning, characterization, and overexpression of the gene encoding Endo-â-GalGnGa and the hypothesis testing of degrading mucus.
Characterizations
Important Parameters
Purification and Identification of EBG
After confirming that the cloning worked, the biobrick plasmid (BBa_K2235010) was transformed into E. coli BL21(DE3) and expression was induced at multiple combinations of OD600 and IPTG concentrations. SDS-PAGE results from one of the successful expressions (at OD600 of 0.4 and an IPTG concentration of 0.5 mM) show the expression of EBG, a 47 kDa protein (figure 6). The band on lane three is believed to be EBG.
EBG Enzymatic Activity on Mucin
To determine the concentration of sugars after the EBG digestion of PGM a colorimetric assay was performed. Industrially available EBG was used firstly to test the assay. The results from the assay were inconclusive as a result of a strong response from the negative control.
Due to time restraints this part of the project was never completed. The next step after fixing the assay would have been to test the expressed EBG from E. coli.
Methods
IMAC purification
To purify the EBG samples and the control based on the containing Histag. The protocol was used with no changes. The colons used for the IMAC purification was one nickel colon with colon volume of 3,2 mL and three cobalt colons, each with colon volumes of 1,2 mL. The protein samples was eluted to five fractions each. SDS-PAGE was performed after IMAC purification to visualize the expressed EBG samples
Ligation of sialidase insert into iGEM backbone
We designed our endo-β-galactosidase (EBG) biobrick (BBa_K2235010) by modifying the sequence of professor Li (Ashida, 2002). The sequence received did not contain a His6-tag, which was added to the sequence for later IMAC purification steps. The biobrick containing T7 promoter-RBS-EBG was cloned into an iGEM compatible plasmid backbone (pSB1C3). To confirm successful cloning, we double digested plasmids from five different colonies (figure 5). For each colony, two bands could be observed. One at ~1400 bp, corresponding to the size of EBG, and one at ~2000 bp, corresponding to the size of the plasmid backbone.
Reference
1. Ashida, H., Anderson, K., Nakayama, J., Maskos, K., Chou, C.-W., Cole, R. B., Li, S.-C., and Li, Y.-T. (2001) J. Biol. Chem. 276, 28226−28232
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21INCOMPATIBLE WITH RFC[21]Illegal BamHI site found at 246
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]